July was the most profitable month (+$49,452 net) despite not being the highest revenue month — overhead dropped across all 3 locations simultaneously. Understanding why and replicating those conditions is the highest-value operational question. April's $246K revenue included $83,446 in government grants — real recurring treatment revenue was ~$162K. February was the worst month at -$36,159 net, driven by Etobicoke overhead of $69,940 on only $77,111 revenue.

The revenue story is actually good — $2.1M across 3 locations with Mississauga growing 14.4% YoY. The profitability story is not. Etobicoke's staff cost at 68.9% of revenue is the entire problem. Closing that gap to 56% (industry max) on $1.13M revenue = approximately $146,000 in additional annual profit without a single new patient.

Etobicoke paid $396,069 to Associates + $399,164 in Payroll = $795,233 in staff costs on $1,153,468 in treatment revenue. That is 68.9 cents of every treatment dollar going to clinical staff. Industry maximum is 56 cents. The difference on Etobicoke's revenue base alone is $146,000/year.

Projections use actual 2025 monthly performance as the baseline. July is the model month — highest net profit despite not being highest revenue, because overhead was controlled. April 2025 is excluded from the base as it contained $83,446 in non-recurring grant income. Conservative case assumes Etobicoke continues losing money. Base case assumes a 5% reduction in associate costs.

Etobicoke paid $396,069 to associates in 2025 — averaging $33,006/month. Mississauga's associate costs rose from $4,350 in Jan 2025 to $22,033 in Nov 2025. Individual therapist performance data must be pulled from Juvonno to identify who is generating revenue vs who is creating cost without corresponding billing. Replace placeholder names below with real therapist data.